| SC 13G | 2024-03-13 | AbbVie Biotechnology Ltd | Carisma Therapeutics Inc. | 2,749,855 | 6.8% | EDGAR |
| SC 13D/A | 2024-03-07 | HealthCap VII, L.P. | Carisma Therapeutics Inc. | 3,398,248 | 8.4% | EDGAR |
| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | Carisma Therapeutics Inc. | 1,568,761 | 3.9% | EDGAR |
| SC 13G/A | 2024-02-02 | Longview Innovation Corp. | Carisma Therapeutics Inc. | 2,713,232 | 6.7% | EDGAR |
| SC 13D/A | 2024-01-26 | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | Carisma Therapeutics Inc. | 1,252,107 | 3.1% | EDGAR |
| SC 13D/A | 2023-03-22 | HealthCap VII, L.P. | Carisma Therapeutics Inc. | 3,398,248 | 8.4% | EDGAR |
| SC 13D | 2023-03-17 | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | Carisma Therapeutics Inc. | 2,182,812 | 5.4% | EDGAR |
| SC 13G | 2023-03-16 | Longview Innovation Corp. | Carisma Therapeutics Inc. | 2,895,265 | 7.2% | EDGAR |
| SC 13G | 2023-03-13 | ModernaTX, Inc. | Carisma Therapeutics Inc. | 5,059,338 | 12.6% | EDGAR |
| SC 13D | 2023-03-09 | HealthCap VII, L.P. | Carisma Therapeutics Inc. | 3,579,611 | 8.9% | EDGAR |
| SC 13D/A | 2023-02-15 | Radoff Bradley Louis | Sesen Bio, Inc. | 1,879,344 | 4.6% | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | Sesen Bio, Inc. | 10,854,300 | 5.4% | EDGAR |
| SC 13D/A | 2023-01-26 | Radoff Bradley Louis | Sesen Bio, Inc. | 1,879,344 | 4.4% | EDGAR |
| SC 13D/A | 2023-01-05 | Radoff Bradley Louis | Sesen Bio, Inc. | 1,879,344 | 4.3% | EDGAR |
| SC 13D/A | 2022-12-01 | Radoff Bradley Louis | Sesen Bio, Inc. | 1,000,000 | 3.7% | EDGAR |
| SC 13D | 2022-11-18 | Radoff Bradley Louis | Sesen Bio, Inc. | 5,600,000 | 2.8% | EDGAR |
| SC 13G | 2022-07-08 | BlackRock Inc. | Sesen Bio, Inc. | 4,088,667 | 2.0% | EDGAR |
| SC 13G | 2022-02-10 | VANGUARD GROUP INC | Sesen Bio, Inc. | 12,366,756 | 6.2% | EDGAR |
| SC 13G | 2022-02-04 | BlackRock Inc. | Sesen Bio, Inc. | 13,488,604 | 6.8% | EDGAR |
| SC 13G | 2021-06-28 | INTEGRATED ASSETS II LLC | Sesen Bio, Inc. | 1,956,170 | 1.1% | EDGAR |